Clinical Trial Detail

NCT ID NCT02576301
Title Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OXiGENE
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Combretastatin A1 Diphosphate

Combretastatin A1 Diphosphate + Cytarabine

Age Groups: adult

No variant requirements are available.